• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.
【24h】

The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.

机译：转铁蛋白受体第二部分：将治疗剂靶向递送至癌细胞。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Traditional anti-cancer treatments consist of chemotherapeutic drugs that effectively eliminate rapidly dividing tumor cells. However, in many cases chemotherapy fails to eliminate the tumor and even when chemotherapy is successful, its systemic cytotoxicity often results in detrimental side effects. To overcome these problems, many laboratories have focused on the design of novel therapies that exhibit tumor specific toxicity. The transferrin receptor (TfR), a cell membrane-associated glycoprotein involved in iron homeostasis and cell growth, has been explored as a target to deliver therapeutics into cancer cells due to its increased expression on malignant cells, accessibility on the cell surface, and constitutive endocytosis. The TfR can be targeted by direct interaction with conjugates of its ligand transferrin (Tf) or by monoclonal antibodies specific for the TfR. In this review we summarize the strategies of targeting the TfR in order to deliver therapeutic agents into tumor cells by receptor-mediated endocytosis.
机译：传统的抗癌治疗方法包括有效消除快速分裂的肿瘤细胞的化学治疗药物。然而，在许多情况下，化学疗法无法消除肿瘤，即使化学疗法成功，其全身细胞毒性也常常导致有害的副作用。为了克服这些问题，许多实验室将重点放在表现出肿瘤特异性毒性的新疗法的设计上。转铁蛋白受体（TfR）是一种参与铁稳态和细胞生长的与细胞膜相关的糖蛋白，由于其在恶性细胞中的表达增加，在细胞表面的可及性以及组成型的作用，已被探索为将治疗剂递送至癌细胞的靶标。内吞作用。可通过与其配体转铁蛋白（Tf）的缀合物直接相互作用或通过对TfR特异的单克隆抗体来靶向TfR。在这篇综述中，我们总结了靶向TfR的策略，以便通过受体介导的内吞作用将治疗剂递送到肿瘤细胞中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号